Hagit Eldar-Finkelman

Tel Aviv University, Tel Aviv-Yafo, Tel Aviv District, Israel 
"Hagit Eldar-Finkelman"
Mean distance: 16.88 (cluster 6)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Grieco SF, Cheng Y, Eldar-Finkelman H, et al. (2016) Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition. Progress in Neuro-Psychopharmacology & Biological Psychiatry
Aloni E, Shapira M, Eldar-Finkelman H, et al. (2015) GSK-3β Inhibition Affects Singing Behavior and Neurogenesis in Adult Songbirds. Brain, Behavior and Evolution. 85: 233-44
Azoulay-Alfaguter I, Elya R, Avrahami L, et al. (2014) Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth. Oncogene
La Pietra V, La Regina G, Coluccia A, et al. (2013) Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors. Journal of Medicinal Chemistry. 56: 10066-78
Avrahami L, Eldar-Finkelman H. (2013) GSK-3 and lysosomes meet in Alzheimer's disease. Communicative & Integrative Biology. 6: e25179
Beurel E, Kaidanovich-Beilin O, Yeh WI, et al. (2013) Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3. Journal of Immunology (Baltimore, Md. : 1950). 190: 5000-11
Avrahami L, Licht-Murava A, Eisenstein M, et al. (2013) GSK-3 inhibition: achieving moderate efficacy with high selectivity. Biochimica Et Biophysica Acta. 1834: 1410-4
Avrahami L, Farfara D, Shaham-Kol M, et al. (2013) Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. The Journal of Biological Chemistry. 288: 1295-306
Lo Monte F, Kramer T, Gu J, et al. (2013) Structure-based optimization of oxadiazole-based GSK-3 inhibitors. European Journal of Medicinal Chemistry. 61: 26-40
Licht-Murava A, Eldar-Finkelman H. (2012) Exploiting substrate recognition for selective inhibition of protein kinases. Current Pharmaceutical Design. 18: 2914-20
See more...